| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | IL22R; CRF2-9; IL22R1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human IL22RA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是几篇关于IL22RA1抗体的模拟参考文献示例(实际文献需通过学术数据库查询)：
1. **文献名称**: *Structural and Functional Characterization of IL22RA1 Antibodies in Autoimmune Disease Models*
**作者**: Smith J, et al.
**摘要**: 本研究通过生成特异性IL22RA1单克隆抗体，揭示了其在抑制IL-22信号通路中的作用。实验表明，该抗体可减轻小鼠模型中结肠炎的症状，提示其在治疗IL-22介导的自身免疫疾病中的潜力。
2. **文献名称**: *IL22RA1 as a Therapeutic Target in Psoriasis: Antibody Blockade Reduces Skin Inflammation*
**作者**: Lee H, et al.
**摘要**: 研究利用抗IL22RA1抗体阻断IL-22与其受体的结合，发现其显著降低银屑病模型小鼠的皮肤炎症反应，表明靶向IL22RA1可能是治疗Th17相关皮肤疾病的新策略。
3. **文献名称**: *Dual Role of IL22RA1 Antibodies in Cancer: Promotion or Inhibition of Tumor Growth*
**作者**: Garcia R, et al.
**摘要**: 本文探讨了IL22RA1抗体在结肠癌中的双重作用。研究发现，IL22RA1在肿瘤微环境中高表达，抗体干预可抑制肿瘤细胞增殖，但可能同时增强某些促炎因子释放，提示需精准调控其应用。
4. **文献名称**: *Development of a High-Affinity IL22RA1 Antibody for Diagnostic Imaging*
**作者**: Chen L, et al.
**摘要**: 研究团队开发了一种高亲和力IL22RA1抗体，用于炎症性肠病(IBD)的活体成像。该抗体可特异性标记肠道炎症区域，为疾病的无创诊断提供了新工具。
建议通过PubMed、Google Scholar等平台检索真实文献，关键词：**IL22RA1 antibody**, **IL-22 receptor**, **therapeutic targeting**。
The IL22RA1 antibody targets the interleukin-22 receptor alpha 1 (IL22RA1), a key subunit of the IL-22 receptor complex. IL22RA1 is a member of the type II cytokine receptor family and pairs with IL-10Rβ to form a functional receptor for IL-22. a cytokine involved in mucosal immunity, tissue repair, and inflammatory responses. IL-22 signaling through IL22RA1 activates downstream pathways like JAK/STAT, particularly STAT3. regulating epithelial cell proliferation, barrier function, and antimicrobial peptide production.
IL22RA1 is primarily expressed on epithelial cells, fibroblasts, and certain immune cells. Its role in diseases has drawn significant interest; dysregulated IL-22/IL22RA1 signaling is linked to autoimmune disorders (e.g., psoriasis, inflammatory bowel disease), chronic inflammation, and cancer. In cancer, IL22RA1 overexpression may promote tumor progression by enhancing cell survival and tissue remodeling.
Antibodies against IL22RA1 are vital tools for research and therapeutic development. They enable detection of receptor expression in tissues, block IL-22 signaling in experimental models, and help evaluate the receptor’s role in pathogenesis. Therapeutic antibodies targeting IL22RA1 are being explored to modulate IL-22 activity in diseases where its pathway is overactive. However, challenges remain in balancing efficacy with potential side effects, as IL-22 also has protective roles in barrier integrity and wound healing. Studies using IL22RA1 antibodies continue to clarify its dual functions in health and disease.
×
